Bridgepoint Development Capital has acquired Quotient Clinical, a provider of early stage drug development services, from the Quotient Bioresearch Group. Quotient Clinical offers a platform that uses an integrated approach to formulation development, realtime drug product manufacturing and clinical testing.
Quotient Clinical employs more than 200 people and has two facilities in the UK. The principal site in Nottingham has an 85-bed clinical pharmacology unit with an integrated drug manufacturing facility, and the second facility in Edinburgh houses the companies’ biometrics function for the analysis and reporting of clinical trial data. Financial terms were not disclosed.
Quotient Clinical chief executive officer Mark Egerton said, “We are very excited at the pace with which our platform is being adopted in the marketplace. Working with Bridgepoint Development Capital will now provide the support to catalyze the next phase of our growth and evolution. Their experience in helping portfolio companies to scale will be invaluable as we endeavor to grow our business and maintain the high levels of customer satisfaction that we currently enjoy.”
Alan Payne, partner at Bridgepoint Development Capital, said, “Quotient Clinical serves a substantial and growing market and there is significant opportunity to increase market penetration thanks to its combination of unique service offering, strong regulatory governance and a talented management team.”
The transaction is subject to standard regulatory clearances. Debt finance for the transaction was provided by HSBC. Advisers for Bridgepoint included Ernst & Young, Travers Smith, and LEK.